

Review Article

Effectivity and Safety Profile of Tenapanor, a Sodium-Hydrogen Exchanger Isoform 3 Inhibitor, as an Innovative Treatment for Hyperphosphatemia in Chronic Kidney Disease, a Systematic Review of Clinical Studies

Running Title: Tenapanor for Hyperphosphatemia in Chronic Kidney Disease

William Suciango¹, Haerani Rasyid², Anastasya Angelica Vicente¹, Winny Suciango¹

¹Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia

²Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia

Corresponding Author: William Suciango, email: williamsuciango@gmail.com

Funding agency: None

Conflict of Interest Declaration: The authors declare that there is no conflict of interest or any financial interest, connection, or other situation that may raise the question of bias of our writing and affect the conclusion we have made.

Author's contribution:

William Suciango: Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing original draft preparation, writing review and editing, visualization, project administration.

Haerani Rasyid: Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing original draft preparation,

writing review and editing, supervision, project administration.

Anastasya Angelica Vicente: Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing original draft preparation, writing review and editing, project administration.

Winny Suciangto: Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing original draft preparation, writing review and editing, project administration.

Abstract

Background: Chronic kidney disease (CKD) is a major global health problem. Hyperphosphatemia is frequent in CKD and a reason for increased morbidity and mortality as it generates hyperparathyroidism, high fibroblast growth factor 23 (FGF23), and hypocalcemia. Available hyperphosphatemia therapies still have limitations, including risk of metal overload, cardiovascular calcification, and systemic adverse effects (AEs). Tenapanor is a new hyperphosphatemia treatment in CKD with sodium-hydrogen exchanger isoform 3 (NHE3) inhibition mechanism and low systemic AEs.

Objectives: Discovering the effectivity and safety of tenapanor as hyperphosphatemia management in CKD. **Method:** Literature searching is performed by using “pubmed” and “science direct” with “tenapanor”, “chronic kidney disease”, and “hyperphosphatemia” as keywords. The literatures were selected using PRISMA algorithm version 2020. Literature was screened based on Population, Intervention, Comparison, and Outcome (PICO) criteria which are: CKD patients requiring dialysis as population, tenapanor or its combination with dialysis or phosphate binders as intervention, placebo or other phosphate binders without tenapanor as comparison, and serum phosphate, safety profile, and other pleiotropic benefits related to hyperphosphatemia management as the outcome. The included studies then assessed for risk of bias and qualitatively reviewed. **Outcome:** Tenapanor was able to reduce serum phosphate, generally in a dose-dependent manner. Tenapanor also suppressed FGF23 and parathyroid hormone, probably due to decreased serum phosphate. The frequent AEs was transient mild-to-moderate diarrhea in a dose-dependent manner. Tenapanor was generally well-tolerated with low systemic AEs due to its non-calcium, metal-free,

and low-absorbed properties. **Conclusion:** Tenapanor is an effective and safe option for hyperphosphatemia management in CKD.

Keywords: Chronic Kidney Disease, Hyperphosphatemia, Tenapanor.

INTRODUCTION

Chronic kidney disease (CKD) is still a major global health problem, with approximately 697.6 million people worldwide were reported to have CKD in 2017, of which 1.2 million people died due to CKD.¹ Hyperphosphatemia is often found in CKD. Declined renal function, particularly in advanced stage will lead to serum phosphate accumulation due to inability in excreting serum phosphate which is mostly originated from daily intestinal absorption. Osteocytes then release fibroblast growth factor 23 (FGF23) in order to promote renal phosphate excretion. Unfortunately, FGF23 also impair renal 1.25-Dihydroxycalcitriol production which disturb intestinal calcium absorption, resulting in hypocalcemia. Parathyroid glands then release parathyroid hormone (PTH) as a compensatory mechanism to increase serum calcium through bone resorption. Calcium and phosphate release from destructed bone will lead to cardiovascular calcification and bone disorders, thus increasing morbidity and mortality in patients with CKD.^{2,3}

Dialysis, phosphate binders, and calcimimetic agents are available modalities for hyperphosphatemia management in CKD, but they still have some disadvantages including flexibility limitation, hypocalcemia risk, as well as metal overload and cardiovascular calcification.⁴⁻⁶ In this review, we provide clinical evidences of the effectivity and safety profile of tenapanor in managing hyperphosphatemia in CKD through its sodium-hydrogen exchanger isoform 3 (NHE3) inhibition.

METHOD

Literature searching was performed in Pubmed and Science Direct by using “tenapanor”, “chronic kidney disease”, and “hyperphosphatemia” as keywords. The studies then systematically selected by using The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) algorithm (Figure. 1). Duplicate literatures were removed. Review articles, books, conferences abstracts, editorials, commentaries, letter to editor, and

guidelines were excluded, while research studies were retrieved. Literature screening was performed by using Population, Intervention, Comparison, and Outcome (PICO) criteria which are: CKD patients requiring dialysis as population, tenapanor or its combination with dialysis or phosphate binders as intervention, placebo or other phosphate binders without tenapanor as comparison, as well as serum phosphate and safety profile as the outcome. Studies which meet the criteria then examined for risk of bias as quality assessment and qualitatively synthesized to establish this systematic review.

RESULT AND DISCUSSION

Risk of Bias Assessment in Included Studies

Our included studies have a relatively similarities in risk of bias. The participants and investigators were all blinded in all of our included studies.⁷⁻¹³ There are two studies with unclear risk of randomization sequence method as it was not mentioned in the studies.^{8,10} Five of included studies have unclear risk of concealment of randomization allocation.^{8,10-13} All of our included studies have a low risk of bias in completeness of reported outcomes.⁷⁻¹³ The general summary of the risk of bias in our included studies can be seen in figure 2.

Characteristics of Included Studies

A total of seven clinical studies were included in our review. All the studies evaluated the decrease of serum phosphate as their primary outcome.⁷⁻¹³ Four studies use tenapanor or placebo alone as the intervention and comparison by implementing “washout system”⁷⁻¹⁰, while the three other studies still maintained the previous phosphate binders as a combination with tenapanor or placebo.¹¹⁻¹³ Six of seven studies also examined FGF23 levels as the other outcome.^{8-11,13,14} The level of PTH was investigated in two studies.^{9,13} All of our included studies evaluated the safety profile of tenapanor. The summary of our included studies is described in table 1.

The Role of Tenapanor as Hyperphosphatemia Treatment in Chronic Kidney Disease

Hyperphosphatemia is a frequent metabolic complication of CKD, particularly in end stage disease. This complication is a result of impaired renal function and limitation of conventional dialysis to eliminate serum phosphate originated from dietary phosphate absorption.^{7,10}

Tenapanor is a selective inhibitor of the sodium-hydrogen exchanger isoform 3 (NHE3), an antiporter located on the surface of the gastrointestinal tract's enterocytes. By inhibiting the sodium-hydrogen exchange, tenapanor causes the accumulation of intracellular protons and subsequently lowers the pH. This decrease in pH alters the tight junction proteins, resulting in a decrease in the permeability of phosphate paracellular diffusion and ultimately lowering the level of serum phosphate.^{7-9,12} The mechanism of tenapanor in inhibiting phosphate absorption can be seen in figure 3.

Effectivity of Tenapanor in Lowering Serum Phosphate in Chronic Kidney Disease

There are four studies which investigated the effect of tenapanor as a single therapy to serum phosphate in CKD patients. All the patients underwent 1-3 weeks of washout period before started the treatment.⁷⁻¹⁰ The majority dose of tenapanor was 3, 10, and 30 mg twice daily (BID)⁷⁻¹⁰, though dosage of 3 and 30 mg once daily^{8,10} as well as 1 and 5 mg BID was also found⁸⁻¹⁰. All these four studies showed a higher decrease in serum phosphate with tenapanor as single therapy compared to placebo.⁷⁻¹⁰ Significant serum phosphate decrement from baseline was reported with tenapanor dose of 3, 5, 10, and 30 mg BID in fixed dose as well as 30 mg BID with titration versus placebo in two studies.⁷⁻⁹ Tenapanor reduces serum phosphate levels in a dose-dependent manner in all four studies.⁷⁻¹⁰ In the other hand, tenapanor as single therapy also resulted in higher proportion of patients achieving serum phosphate target of <5.5 mg/dL compared to placebo.⁸

Efficacy of tenapanor as combination therapy with other phosphate binders was observed in three studies. All the subjects in the studies maintained their pre-existing

phosphate binders which then added with tenapanor or placebo.¹¹⁻¹³ Two of three studies use tenapanor 30 mg BID as the treatment¹¹, while one study use tenapanor 5 mg BID¹³. In all three studies, combination of tenapanor with phosphate binders revealed a greater reduction of serum phosphate compared to combination of placebo with phosphate binders.¹¹⁻¹³ Statistical significance was found in two of three studies with tenapanor dose of both 5 mg BID and 30 mg BID.^{11,13} A higher rate of target achievement for serum phosphate was also found in tenapanor group compared to placebo in all three studies¹¹⁻¹³, in which two of three studies set the serum phosphate target to <5.5 mg/dL^{11,12}, while serum phosphate goal ranged from 3.5-6.0 mg/dL in one other study¹³.

Pleiotropic Effect of Tenapanor in Interfering Fibroblast Growth Factor 23 and Parathyroid Hormone in Chronic Kidney Disease

Besides reducing serum phosphate, tenapanor was also found to have a beneficial effect on FGF23 and PTH levels. A total of six studies showed FGF23 declined with tenapanor^{8-11,13,14}. Significant decrease in FGF23 was observed in tenapanor as single therapy at dose of 1, 3, 10, and 30 mg BID as well as 3 and 30 mg once daily.^{7,8,10} Tenapanor as combination therapy with other phosphate binders also showed its ability in reducing FGF23 levels at dose of both 5 mg and 30 mg BID.^{11,13}

Tenapanor was also found to suppress PTH levels other than serum phosphate and FGF23 in two studies.^{9,13} As monotherapy, tenapanor at dose of 5, 10, and 30 mg BID was able to reduce PTH levels though the significance was not reported.⁹ In a setting as combination therapy with other phosphate binders, tenapanor 5 mg BID was reported to significantly suppress PTH.¹³

Safety Profile of Tenapanor in Chronic Kidney Disease Population

Safety profile of tenapanor was evaluated in all of our included studies.⁷⁻¹³ Gastrointestinal symptoms especially diarrhea was the most frequent adverse effect (AE) in

all the studies.⁷⁻¹³ The intensity of diarrhea was dominantly mild to moderate in severity with transient onset in majority of studies.¹¹⁻¹³ In the setting of tenapanor as single therapy, the diarrhea tended to be dose-dependent, as the incidence of diarrhea was higher in tenapanor dose of 10 mg and 30 mg BID as well as 30 mg once daily.⁷⁻¹⁰ The same trend was also found in the setting of tenapanor as combination therapy with phosphate binders, in which higher incidence of diarrhea was reported in studies with higher dose of tenapanor.¹¹⁻¹³ Severe diarrhea was reported in one study, which is predominantly in tenapanor dose of 30 mg once and twice daily.¹⁵

The safety profile of tenapanor was also evaluated with physical examination, laboratory, and electrocardiography (ECG) parameters. In our included studies, tenapanor therapy didn't lead to any significant change in physical examination, laboratory, and ECG parameters. There was also no death related to tenapanor. From these findings, tenapanor was relatively safe and well tolerated in CKD patients.^{7-9,11,12}

Discussion

Phosphate retention is frequently found in CKD stage 4 and 5, which is a factor that initiate many other disturbances such as increased FGF23 and PTH, hypocalcemia, and low vitamin D, which in turn will lead to an enhancement in cardiovascular and all cause of morbidity and mortality.¹⁶ Phosphate balance is maintained by several mechanism including intestinal phosphate absorption, bone turnover regulation, as well as renal excretion and reabsorption.^{4,17} In a normal condition, kidney excretes approximately ninety percent of phosphate per day.¹⁸ As renal phosphate clearance declined in CKD, inhibiting intestinal phosphate absorption can be a promising approach in managing hyperphosphatemia in patients with CKD.^{4,18}

Generally, phosphate binders only result in maximum 2.0 mg/dL of phosphate reduction in their maximal dose.⁷ Some of our included studies show that 30 mg tenapanor

whether as fixed or titrated dose single therapy was able to reduce serum phosphate up to more than 2.0 mg/dL.^{7,8} This finding can be possible due to tenapanor mechanism which suppress intestinal phosphate absorption through NHE3 inhibition^{7-9,12}, as about 90% of phosphate input comes from intestinal absorption.¹⁸

In addition to its phosphate lowering effect, tenapanor was also found to have a pleiotropic effect in suppressing the levels of FGF23 and PTH, both as monotherapy and combination therapy with phosphate binders.^{8-11,13,14} The exact mechanism of this finding remains unclear, but it can be possibly explained by the role of these two hormones as compensatory mechanism to elevated serum phosphate, thus greater reduction of serum phosphate will suppress FGF23 and PTH production.^{7,9,10,13} This pleiotropic effect of tenapanor can be utilized to minimize the morbidity and mortality in CKD, as high FGF23 and PTH will cause extraosseous calcium and phosphate deposition, particularly in the heart valves and vascular. This condition then develop to valve and vascular atherosclerosis through osteochondrogenic differentiation and elastin degradation, leading to increased mortality due to cardiovascular disease.¹⁹ Besides that, increased PTH which enhance calcium efflux from bones is the cause of bone mass loss in patients with CKD, resulting in increased morbidity.²⁰ Therefore, the pleiotropic effect of tenapanor in lowering FGF23 and PTH suggesting its potency as future treatment for bone mineral disease and secondary hyperparathyroidism in CKD.

Diarrhea is the most common AE caused by tenapanor. However, majority of reported diarrhea was transient and mild to moderate in intensity.¹¹⁻¹³ This side effect appears as the effect of tenapanor mechanism which selectively inhibit the NHE3 in enterocytes, thus suppress the passive transport of phosphate in the intestine. Simultaneously, NHE3 inhibition also suppress intestinal sodium absorption which enhance sodium and water secretion in the

intestinal tract.^{8,9} Elevated sodium, phosphate, and water content in the intestine then lead to loose stool and increased bowel movement which manifested as diarrhea.^{7,13} Incidence of diarrhea due to tenapanor has a higher trend in higher dose.⁷⁻¹³ Dose titration can be a good solution for this issue to increase patient's compliance, as titrated dose of tenapanor 30 mg BID exhibited a lower incidence of diarrhea while maintaining the same efficacy in reducing serum phosphate and FGF23 compared to fixed dose of tenapanor 30 mg BID.⁹

Minerals deposition and metabolic disturbances are the other concerns in treatment options for hyperphosphatemia in CKD. Available phosphate binders still has systemic mineral and metabolic disadvantages, such as calcium accumulation and increased calcification in calcium based phosphate binders, potential nervous system toxicity in aluminium based phosphate binders, iron overload in iron based phosphate binders, fat-soluble vitamins deficiency and acidosis risk in sevelamer based phosphate binders, as well as possible lanthanum deposits in lanthanum based phosphate binders.⁴⁻⁶ Tenapanor comes as a solution to counteract these limitations, as tenapanor didn't cause any meaningful changes in serum calcium, laboratory parameters, ECG, and physical examination.^{7-9,11,12} The plausible explanation for this finding is the nature of tenapanor as a calcium free non-metal phosphate reducer, thus it doesn't cause calcium and metal accumulation. In addition, tenapanor is also a minimally absorbed molecule, resulting in minimum systemic side-effect.^{7,8}

CONCLUSION AND RECOMMENDATION

In conclusion, tenapanor, as single therapy or combination with phosphate binders, was effective in managing hyperphosphatemia in CKD. It also has pleiotropic effects in interfering high FGF23 and PTH thus exhibit a promising potency to treat secondary hyperparathyroidism in CKD. Diarrhea is the most common AE but it's only transient, dose-related, and mild to moderate in severity. Starting tenapanor with low dose can be a solution for diarrhea side effect. Tenapanor doesn't cause any meaningful change in ECG, serum

calcium, and other laboratory and clinical parameters. Generally, tenapanor is safe and well-tolerated in CKD patients.

ACKNOWLEDGMENT

-

REFERENCE

1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709–33. [https://doi.org/10.1016/S0140-6736\(20\)30045-3](https://doi.org/10.1016/S0140-6736(20)30045-3)
2. Bacchetta J, Bernardor J, Garnier C, Naud C, Ranchin B. Hyperphosphatemia and Chronic Kidney Disease□: A Major Daily Concern Both in Adults and in Children. *Calcif Tissue Int* [Internet]. 2020;(0123456789). Available from: <https://doi.org/10.1007/s00223-020-00665-8> doi: 10.1007/s00223-020-00665-8
3. Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. *Kidney Int* [Internet]. 2018;93(5):1060–72. Available from: <https://doi.org/10.1016/j.kint.2017.11.036> doi: 10.1016/j.kint.2017.11.036
4. Rastogi A, Bhatt N, Rossetti S. Management of Hyperphosphatemia in End-Stage Renal Disease□: A New Paradigm. *J Ren Nutr* [Internet]. 2021;31(1):21–34. Available from: <https://doi.org/10.1053/j.jrn.2020.02.003> doi: 10.1053/j.jrn.2020.02.003
5. Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, et al. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective. *Am J Kidney Dis*. 2021;77(1):132–41. <https://doi.org/10.1053/j.ajkd.2020.05.025>
6. Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. *Aust Prescr*. 2017;40(1):9–14. <https://doi.org/10.18773/austprescr.2017.002>
7. Block GA. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis□: A Randomized Phase 3 Trial. 2019;30(4):641–52. <https://doi.org/10.1681/ASN.2018080832>

8. Block GA. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. 2017;28(6):1933–42. <https://doi.org/10.1681/ASN.2016080855>
9. Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. *Kidney Int Reports* [Internet]. 2022;7(2):177–88. Available from: <https://doi.org/10.1016/j.ekir.2021.11.008> doi: 10.1016/j.ekir.2021.11.008
10. Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. 2019;(April 2018):339–46. <https://doi.org/10.1093/ndt/gfy061>
11. Pergola PE. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). 2021;32(6):1465–73. <https://doi.org/10.1681/ASN.2020101398>
12. Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia. 2021;496–506. <https://doi.org/10.1159/000516156>
13. Nitta K, Itoyama S, Ikejiri K, Kinoshita J, Nakanishi K, Fukagawa M, et al. Randomized Study of Tenapanor Added. *Kidney Int Reports* [Internet]. 2021;(July):1–11. Available from: <https://doi.org/10.1016/j.ekir.2023.08.003> doi: 10.1016/j.ekir.2023.08.003
14. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm. Vol. 140, *Circulation*. 2019. 382–482 p. <https://doi.org/10.1161/CIR.0000000000000628>

15. Navarro-Lopez V, Ramirez-Bosca A, Ramon-Vidal D, Ruzafa-Costas B, Genoves-Martinez S, Chenoll-Cuadros E, et al. Effect of oral administration of a mixture of probiotic strains on SCORAD index and use of topical steroids in young patients with moderate atopic dermatitis a randomized clinical trial. *JAMA Dermatology*. 2018;154(1):37–43. <https://doi.org/10.1001/jamadermatol.2017.3647>
16. Sprague SM, Martin KJ, Coyne DW. Phosphate Balance and CKD–Mineral Bone Disease. *Kidney Int Reports* [Internet]. 2021;6(8):2049–58. Available from: <https://doi.org/10.1016/j.ekir.2021.05.012> doi: 10.1016/j.ekir.2021.05.012
17. Tsuchiya K, Akihisa T. The importance of phosphate control in chronic kidney disease. *Nutrients*. 2021;13(5):1–22. <https://doi.org/10.3390/nu13051670>
18. Goyal R, Jialal I. Hyperphosphatemia. StatPearls NCBI Bookshelf; 2023. 11 p.
19. Yamada S, Giachelli CM. Vascular Calcification in CKD-MBD: Roles for Phosphate, FGF23, and Klotho. *Bone*. 2017;100:87–93. <https://doi.org/10.1016/j.bone.2016.11.012>. Vascular
20. Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. *Semin Dial*. 2015;28(6):564–77. <https://doi.org/10.1111/sdi.12411>

Tables and Figures

Table 1. Table of Included Studies

Authors, Years	Study Design	Population	Intervention (I) and Comparison (C)	Outcomes
Pergola et al, 2021	Multicenter, double blind, randomized placebo-controlled trial (RCT), phase 3	N = 235. CKD patients receiving regular hemodialysis (HD) with hyperphosphatemia.	I: Oral tenapanor 30 mg twice daily (BID) + pre-existing phosphate binder. C: Oral placebo BID + pre-existing binder.	Significantly larger change in serum phosphorus from baseline to week 4 in tenapanor + binder group compared to placebo + binder (p<0.001). Significantly larger proportion of patients achieved serum phosphorus <5.5 mg/dl in tenapanor + binder group compared to placebo + binder (p<0.01). Significant FGF23 reductions in tenapanor + binder group (p=0.003). Transient mild to moderate diarrhea was the most common adverse effect (AE) with tenapanor + binder, resolved with dose adjustment. No clinical meaningful change in laboratory, electrocardiogram (ECG), and physical examination.

				No serious AE and death were related to treatment.
Block et al, 2019	Double blind, RCT, phase 3. Consists of randomized treatment period (RTP) and randomized withdrawal period (RWP)	N =164 in RTP, 152 in RWP. Patients with end stage kidney disease (ESKD) receiving maintenance HD.	RTP: I: tenapanor regimens— 3 or 10 mg fixed dose BID, or 30 mg BID which could be titrated. C: - RWP: I: previously assigned dose of tenapanor C: placebo	RTP: significant decreased serum phosphate in all three tenapanor groups. Reduction of FGF23 in all three tenapanor groups, significant reduction observed in the 3 and 30 mg BID. RWP: significant change in serum phosphate between pooled tenapanor group compared to placebo (p=0.003). Diarrhea was the most common AE. There was no treatment discontinuation in RWP. No clinical meaningful change in laboratory, ECG, and physical examination. There was no death related to treatment.
Block et al, 2017	Multicenter, double blind,	N = 162	I: one of six tenapanor	Tenapanor resulted in dose-dependent reduced serum phosphate.

	RCT	Patients with ESKD receiving maintenance HD with hyperphosphatemia	regimens (3 or 30 mg once daily or 1, 3, 10, or 30 mg BID) C: placebo.	Largest reductions were found in the tenapanor 10 and 30 mg BID compared to placebo ($p<0.05$). Proportion of patients reached serum phosphate <5.5 mg/dL in tenapanor was up to 43%, while in placebo only 8%. Significant FGF23 reduction in all tenapanor groups compared to placebo ($p<0.05$). The most frequent AE was GI symptoms (diarrhea), mostly mild to moderate. Severe diarrhea predominantly in tenapanor 30 mg once or twice daily. No serious AE was related to the treatment. No clinically relevant changes in serum calcium, potassium, or sodium.
Shigematsu et al, 2021	Multicenter, double blind, RCT.	N = 47 CKD patients receiving HD with	I: Tenapanor 30 mg BID + pre-existing phosphate	Larger serum phosphate decrement in tenapanor compared to placebo group. Target achievement of phosphorus

		hyperphosphatemia.	binders. C: Placebo + pre-existing phosphate binders.	<5.5 mg/dL was 73.9% with tenapanor + binder and 25% in placebo + binder. Dominant AE was GI symptoms especially transient non-severe diarrhea. There were no significant changes in laboratory, vital signs, or ECG. There was no serious AE and death related to treatment.
Inaba et al, 2021	Multicenter, double blind, RCT, phase 2.	N = 207 CKD patients receiving HD with hyperphosphatemia.	I: Tenapanor 5-mg BID, 10-mg BID, 30-mg BID, and 30-mg BID with dose titration. Dose adjustment was only for dose-titration group. C: placebo	Significantly reduced serum phosphate in each tenapanor dosage groups compared to placebo (p<0.001). No significant changes in serum Ca in any group. Intact PTH and FGF23 decreased in tenapanor groups. Mild to moderate diarrhea was the most frequent AE and it was dose-related, mostly in 30 mg BID group. There was no severe diarrhea in tenapanor groups.

				No clinically relevant alterations in vital signs, laboratory, or electrocardiogram. There were no deaths during the study.
Block et al, 2019	Multicenter, double blind, RCT, phase 2B.	N = 162 Patients with ESKD receiving HD with hyperphosphatemia.	I: One of six tenapanor regimens (3 or 30 mg once daily, or 1, 3, 10 or 30 mg BID). C: placebo.	Tenapanor decrease serum phosphate in dose-dependent manner compared to placebo. Highest serum phosphate reduction was in tenapanor 10 and 30 mg BID ($p < 0.05$ for each groups vs placebo). FGF23 was significantly reduced in range of 2030–3563 pg/mL in all tenapanor groups ($p < 0.001-0.04$), while FGF23 continued to increase in placebo group. Tenapanor dose of at least 3 mg per day was needed to significantly reduce FGF23. GI disorders (diarrhea) was the common AE, particularly in high tenapanor groups of 10 BID, 30 mg once daily, and 30 mg BID.

Nitta et al, 2023	Double blind, RCT, phase 3.	N = 169 CKD patients receiving HD with hyperphosphatemia.	I: Tenapanor 5 mg BID + pre-existing phosphate binders. C: Placebo + pre-existing phosphate binders.	Significantly reduced serum phosphate from baseline in tenapanor compared to placebo (p<0.0001). Higher proportion of serum phosphate target achievement in tenapanor compared to placebo. Serum FGF and PTH were significantly decreased in tenapanor group, while increased in placebo group. Diarrhea was the dominant AE, all were mild to moderate. There was no treatment discontinuation due to diarrhea.
-------------------	-----------------------------	--	---	---

Figure 1




Figure 1. Literature Screening Algorithm by Using “The Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) version 2020.

Figure 2




Figure 2. Risk of Bias Assessment of Included Studies.

Figure 3




Figure 3. Tenapanor, Mechanism of Action

Identification of studies via databases and registers

Identification

Records identified from*:
Pubmed (n = 30)
Science Direct (n = 72)

Records removed *before screening*:
Duplicate records removed (n = 4)

Screening

Records screened
(n = 98)

Reports excluded:
Review articles (n = 33)
Books (n = 8)
Conference abstracts (n = 27)
Editorials (n = 2)
Commentary (n = 1)
Letter to editor (n = 1)
Guideline (n = 1)
Others (n = 5)

Reports sought for retrieval
Research articles (n = 20)


Reports not retrieved
Invitro/animal only studies (n = 3)

Reports assessed for
eligibility (n = 17)


Reports excluded:
Wrong population and outcome (n = 5)
No comparison (n = 1)
Wong intervention (n = 4)

Include

Studies included in review
(n = 7)



	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Block 2017	?	?	+	+	+	+
Block 2019	+	+	+	+	+	+
Block 2019a	?	?	+	+	+	+
Inaba 2022	+	+	+	+	+	+
Nitta 2021	+	?	+	+	+	+
Pergola 2021	+	?	+	+	+	+
Shigematsu 2021	+	?	+	+	+	+



	- light resistance (chlorine pump)
	- light resistance

Table 1. Table of Included Studies

Authors, Years	Study Design	Population	Intervention (I) and Comparison (C)	Outcomes
Pergola et al, 2021	Multicenter, double blind, randomized placebo-controlled trial (RCT), phase 3	N = 235. CKD patients receiving regular hemodialysis (HD) with hyperphosphatemia.	I: Oral tenapanor 30 mg twice daily (BID) + pre-existing phosphate binder. C: Oral placebo BID + pre-existing binder.	Significantly larger change in serum phosphorus from baseline to week 4 in tenapanor + binder group compared to placebo + binder (p<0.001). Significantly larger proportion of patients achieved serum phosphorus <5.5 mg/dl in tenapanor + binder group compared to placebo + binder (p<0.01). Significant FGF23 reductions in tenapanor + binder group (p=0.003). Transient mild to moderate diarrhea was the most common adverse effect (AE) with tenapanor + binder, resolved with dose adjustment. No clinical meaningful change in laboratory, electrocardiogram (ECG), and physical examination. No serious AE and death were

				related to treatment.
Block et al, 2019	Double blind, RCT, phase 3. Consists of randomized treatment period (RTP) and randomized withdrawal period (RWP)	N =164 in RTP, 152 in RWP. Patients with end stage kidney disease (ESKD) receiving maintenance HD.	RTP: I: tenapanor regimens— 3 or 10 mg fixed dose BID, or 30 mg BID which could be titrated. C: - RWP: I: previously assigned dose of tenapanor C: placebo	RTP: significant decreased serum phosphate in all three tenapanor groups. Reduction of FGF23 in all three tenapanor groups, significant reduction observed in the 3 and 30 mg BID. RWP: significant change in serum phosphate between pooled tenapanor group compared to placebo (p=0.003). Diarrhea was the most common AE. There was no treatment discontinuation in RWP. No clinical meaningful change in laboratory, ECG, and physical examination. There was no death related to treatment.
Block et al, 2017	Multicenter, double blind, RCT	N = 162 Patients with ESKD	I: one of six tenapanor regimens (3 or 30	Tenapanor resulted in dose-dependent reduced serum phosphate. Largest reductions were found in the

		receiving maintenance HD with hyperphosphatemia	mg once daily or 1, 3, 10, or 30 mg BID) C: placebo.	tenapanor 10 and 30 mg BID compared to placebo (p<0.05). Proportion of patients reached serum phosphate <5.5 mg/dL in tenapanor was up to 43%, while in placebo only 8%. Significant FGF23 reduction in all tenapanor groups compared to placebo (p<0.05). The most frequent AE was GI symptoms (diarrhea), mostly mild to moderate. Severe diarrhea predominantly in tenapanor 30 mg once or twice daily. No serious AE was related to the treatment. No clinically relevant changes in serum calcium, potassium, or sodium.
--	--	--	---	---

Shigematsu et al, 2021	Multicenter, double blind, RCT.	N = 47 CKD patients receiving HD with hyperphosphatemia.	I: Tenapanor 30 mg BID + pre-existing phosphate binders. C: Placebo + pre-existing phosphate binders.	Larger serum phosphate decrement in tenapanor compared to placebo group. Target achievement of phosphorus <5.5 mg/dL was 73.9% with tenapanor + binder and 25% in placebo + binder. Dominant AE was GI symptoms especially transient non-severe diarrhea. There were no significant changes in laboratory, vital signs, or ECG. There was no serious AE and death related to treatment.
Inaba et al, 2021	Multicenter, double blind, RCT, phase 2.	N = 207 CKD patients receiving HD with hyperphosphatemia.	I: Tenapanor 5-mg BID, 10-mg BID, 30-mg BID, and 30-mg BID with dose titration. Dose adjustment was only for	Significantly reduced serum phosphate in each tenapanor dosage groups compared to placebo (p<0.001). No significant changes in serum Ca in any group. Intact PTH and FGF23 decreased in tenapanor groups.

			dose-titration group. C: placebo	Mild to moderate diarrhea was the most frequent AE and it was dose-related, mostly in 30 mg BID group. There was no severe diarrhea in tenapanor groups. No clinically relevant alterations in vital signs, laboratory, or electrocardiogram. There were no deaths during the study.
Block et al, 2019	Multicenter, double blind, RCT, phase 2B.	N = 162 Patients with ESKD receiving HD with hyperphosphatemia.	I: One of six tenapanor regimens (3 or 30 mg once daily, or 1, 3, 10 or 30 mg BID). C: placebo.	Tenapanor decrease serum phosphate in dose-dependent manner compared to placebo. Highest serum phosphate reduction was in tenapanor 10 and 30 mg BID ($p < 0.05$ for each groups vs placebo). FGF23 was significantly reduced in range of 2030–3563 pg/mL in all tenapanor groups ($p < 0.001-0.04$), while FGF23 continued to increase in placebo group. Tenapanor dose of at least 3 mg per

				day was needed to significantly reduce FGF23. GI disorders (diarrhea) was the common AE, particularly in high tenapanor groups of 10 BID, 30 mg once daily, and 30 mg BID.
Nitta et al, 2023	Double blind, RCT, phase 3.	N = 169 CKD patients receiving HD with hyperphosphatemia.	I: Tenapanor 5 mg BID + pre-existing phosphate binders. C: Placebo + pre-existing phosphate binders.	Significantly reduced serum phosphate from baseline in tenapanor compared to placebo (p<0.0001). Higher proportion of serum phosphate target achievement in tenapanor compared to placebo. Serum FGF and PTH were significantly decreased in tenapanor group, while increased in placebo group. Diarrhea was the dominant AE, all were mild to moderate. There was no treatment discontinuation due to diarrhea.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

--	--	--	--	--